This nonrandomized phase 2 trial examines remission after combination therapy with ibrutinib and venetoclax in treatment-naive patients with chronic lymphocytic leukemia.
This nonrandomized phase 2 trial examines remission after combination therapy with ibrutinib and venetoclax in treatment-naive patients with chronic lymphocytic leukemia.
Phase II data of frontline Ibrutinib and Venetoclax in 80 higher risk and older CLL patients. Patients had either del(17p) (18%), TP53-mutation (14%), unmutated IGVH, or age>65. 75% achieved MRD negativity in the marrow and estimated 3 year PFS was 93%.